Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Acyl-CoA oxidase is a peroxisomal flavoprotein and the first committed enzyme in peroxisomal β-oxidation, responsible for the desaturation of acyl-CoA substrates, transferring electrons to FAD and then to molecular oxygen to form hydrogen peroxide. This distinguishes it from acyl-CoA dehydrogenase in mitochondria, which routes electrons to the electron transport chain. Subtypes with defined substrate specificities exist: e.g., ACOX1 for straight-chain fatty acids, ACOX2 for branched-chain fatty acids, and ACOX3 for bile acid CoA derivatives. Deficiency or dysfunction causes severe metabolic and neurologic disease, particularly due to VLCFA accumulation and secondary inflammation/degeneration in nervous tissue. The enzyme has a well-resolved crystal structure and is evolutionarily conserved among eukaryotes.
Drugs (notably experimental) that influence Acyl-CoA oxidase typically act by modulation of gene expression (e.g., PPAR agonists), enzyme inhibition or activation, or by affecting peroxisomal function in general.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Acyl-CoA oxidase (ACOX).